Open access · CC-BY
via OpenAlex
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice
Samuel A.J. Trammell, Benjamin J. Weidemann, Ankita Chadda, Matthew S. Yorek, Amey Jo Holmes, Lawrence J. Coppey, Alexander A. Obrosov, Randy H. Kardon, Mark A. Yorek, Charles Brenner
Scientific Reports · 2016 · ▲ 300 citations
Abstract
Male C57BL/6J mice raised on high fat diet (HFD) become prediabetic and develop insulin resistance and sensory neuropathy. The same mice given low doses of streptozotocin are a model of type 2 diabetes (T2D), developing hyperglycemia, severe insulin resistance and diabetic peripheral neuropathy involving sensory and motor neurons. Because of suggestions that increased NAD(+) metabolism might address glycemic control and be neuroprotective, we treated prediabetic and T2D mice with nicotinamide riboside (NR) added to HFD. NR improved glucose tolerance, reduced weight gain, liver damage and the development of hepatic steatosis in prediabetic mice while protecting against sensory neuropathy. In T2D mice, NR greatly reduced non-fasting and fasting blood glucose, weight gain and hepatic steatosis while protecting against diabetic neuropathy. The neuroprotective effect of NR could not be explained by glycemic control alone. Corneal confocal microscopy was the most sensitive measure of neurodegeneration. This assay allowed detection of the protective effect of NR on small nerve structures in living mice. Quantitative metabolomics established that hepatic NADP(+) and NADPH levels were significantly degraded in prediabetes and T2D but were largely protected when mice were supplemented with NR. The data justify testing of NR in human models of obesity, T2D and associated neuropathies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/srep26933
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Trammell, S.A., Weidemann, B.J., Chadda, A., Yorek, M.S., Holmes, A.J., Coppey, L.J., Obrosov, A.A., Kardon, R.H., Yorek, M.A., & Brenner, C. (2016). Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. <em>Scientific Reports</em>. https://doi.org/10.1038/srep26933
Vancouver
Trammell SA, Weidemann BJ, Chadda A, Yorek MS, Holmes AJ, Coppey LJ, et al. Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. Scientific Reports. 2016. doi:10.1038/srep26933.
BibTeX
@article{samuel2016Nicoti,
title = {Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice},
author = {Samuel A.J. Trammell and Benjamin J. Weidemann and Ankita Chadda and Matthew S. Yorek and Amey Jo Holmes and Lawrence J. Coppey and Alexander A. Obrosov and Randy H. Kardon and Mark A. Yorek and Charles Brenner},
journal = {Scientific Reports},
year = {2016},
doi = {10.1038/srep26933},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
PeerJ 2019
Open access · CC-BY
Nicotinamide riboside exerts protective effect against aging-induced NAFLD-like hepatic dysfunction in mice
University of Wisconsin, Madison 2017
Open access · US-GOV
Diet and Exercise Trial to Improve Insulin Resistance, Increase Cerebral Blood Flow, Alter Metabolomic Biomarkers, and Decrease Alzheimer's Disease Risk
PeerJ 2019
Open access · CC-BY
Peer Review #1 of "Nicotinamide riboside exerts protective effect against aging-induced NAFLD-like hepatic dysfunction in mice (v0.1)"
Experimental and Therapeutic Medicine 2021
Open access · CC-BY
Effects of intermittent fasting on liver physiology and metabolism in mice
Basic Research in Cardiology 2024
Open access · CC-BY
Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside
International Journal of Molecular Sciences 2022
Open access · CC-BY